Oslo, Norway, 9 March 2022 - Targovax ASA (OSE: TRVX), a clinical stage immuno
-oncology company developing immune activators to target hard-to-treat solid
tumors, today announces that an abstract has been accepted for poster
presentation at the American Association for Cancer Research (AACR) Annual
Meeting.

The abstracts show ONCOS-102 drives pro-inflammatory modulation of the tumor
micro-environment in PD-1 refractory melanoma tumors. ONCOS-102 is associated
with efficient viral gene expression and strong, sustained activation of immune
-related genes, which may be targets for future combinations of ONCOS-102 and
immune-modulators beyond PD-1/PD-L1 inhibitors.

The abstract has been released on the AACR website today
(https://www.aacr.org/meeting/aacr-annual-meeting-2022/abstracts/). The poster
is scheduled for presentation Monday 11 April 2022 and will be available on
Targovax's website (https://www.targovax.com/en/oncos-oncolytic-virus
-publications-posters-and-oral-presentations/) after the presentation.

Poster      Modulation of immune gene expression by intra-tumoral oncolytic
title:      adenovirus ONCOS-102 is associated with clinical response in anti
            -PD-1 refractory/resistant melanoma
Date and    Monday 11 April 2022, 13:30- 17:00 CDT / 20:30-24:00 CET
time:
Location:   New Orleans Convention Center, Exhibit Halls D-H, Poster Section
            31
Session     Clinical research excluding trials
category:
Session     Immune response to therapies / immune monitoring and clinical
title:      correlate
Poster      1983
number:
Presenter:  Thomas Birkballe Hansen, VP Research, Targovax

About AACR

The AACR Annual Meeting is the focal point of the cancer research community,
where scientists, clinicians, other health care professionals, survivors,
patients, and advocates gather to share the latest advances in cancer science
and medicine. From population science and prevention